EONS15 Nursing Considerations with EGFR Inhibitors in NSCLC
Despite significant advances in the last several years, lung cancer remains the top cause of cancer mortality in 2021. Over the last decade, the oncology community has seen the treatment landscape change, first with the introduction of chemotherapy based on pathologic subtype, and then with targeted agents targeting specific identifiable receptors, making therapy more personalized for patients who express driver mutations. As with any new class of medicines, nurses and other healthcare workers must assume increased responsibility for understanding and managing adverse effects.
EGFRIs is commonly used in non-small cell lung cancer (NSCLC). In compared to cytotoxic chemotherapies, these medicines have resulted in higher response rates and survival. However, despite these benefits, some toxicities are occurred related to the EGFRIs. Therefore, it is so important to symptom management related to EGFRIs in NSCLC.
Reasons to participate:
- To understand the benefits of EGFRIs in NSCLC
- To further your understanding of the symptoms management of the EGFRIs in NSCLC to increase patients’ quality of life
- To better understand symptom management of the EGFRIs in NSCLC to increase patients’ quality of life.
Register for EONS15 here: http://bitly.ws/pXWr
Join the conversation and stay tuned using the hashtags #EONS15 #ESMO22 and #EONS15LungCancer.
Supported by Janssen-Cilag International NV.